Valeant Pharmaceuticals International, Inc.
|Valeant Pharmaceuticals International, Inc. Patent applications|
|Patent application number||Title||Published|
|20140105832||COMPOSITIONS AND METHODS FOR TEETH WHITENING - Disclosed herein are teeth whitening compositions generally including an oxidizing agent, and an activating agent that has an emission wavelength between about 400 nm and about 570 nm. Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.||04-17-2014|
|20110003850||DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS - This invention provides a compound of formula IA||01-06-2011|
|20090170885||NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS - This invention provided compounds of formula I||07-02-2009|
|20090137635||DERIVATIVES OF 5-AMINO-4,6-DISUBSTITUTED INDOLE AND 5-AMINO-4,6-DISUBSTITUTED INDOLINE AS POTASSIUM CHANNEL MODULATORS - This invention provides compounds of formula I||05-28-2009|
|20080213218||METHOD FOR TREATING HEPATITIS C VIRUS INFECTION IN TREATMENT FAILURE PATIENTS - The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relaspe. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen.||09-04-2008|
Patent applications by Valeant Pharmaceuticals International, Inc.